NO20070174L - Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi - Google Patents

Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Info

Publication number
NO20070174L
NO20070174L NO20070174A NO20070174A NO20070174L NO 20070174 L NO20070174 L NO 20070174L NO 20070174 A NO20070174 A NO 20070174A NO 20070174 A NO20070174 A NO 20070174A NO 20070174 L NO20070174 L NO 20070174L
Authority
NO
Norway
Prior art keywords
insulin
preparations
control
prevention
methods
Prior art date
Application number
NO20070174A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel T Green
Robert R Henry
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of NO20070174L publication Critical patent/NO20070174L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20070174A 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi NO20070174L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
NO20070174L true NO20070174L (no) 2007-03-13

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070174A NO20070174L (no) 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Country Status (11)

Country Link
EP (1) EP1778266A4 (enrdf_load_stackoverflow)
JP (1) JP2008505087A (enrdf_load_stackoverflow)
KR (1) KR20070029276A (enrdf_load_stackoverflow)
CN (1) CN101001638A (enrdf_load_stackoverflow)
AU (1) AU2005260025A1 (enrdf_load_stackoverflow)
CA (1) CA2571030A1 (enrdf_load_stackoverflow)
IL (1) IL180361A0 (enrdf_load_stackoverflow)
MX (1) MXPA06014970A (enrdf_load_stackoverflow)
NO (1) NO20070174L (enrdf_load_stackoverflow)
WO (1) WO2006004696A2 (enrdf_load_stackoverflow)
ZA (1) ZA200700708B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816114C (en) 2010-11-03 2019-02-12 Jan Jezek Novel composition comprising glucagon
EP3344231B1 (en) * 2015-09-04 2022-04-13 Latitude Pharmaceuticals, Inc. Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
EP3576748B1 (en) * 2017-02-03 2023-04-05 Vanderbilt University Systems, compositions and methods for treating diabetes
CN110913888A (zh) * 2017-07-14 2020-03-24 Xeris药物公司 治疗先天性高胰岛素血症的方法
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
MX2022016265A (es) * 2020-06-26 2023-02-09 Xeris Pharmaceuticals Inc Composiciones terapeuticas de liberacion sostenida estable en solventes polares aproticos y metodos de preparacion de los mismos.
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
WO2004046106A1 (en) * 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Also Published As

Publication number Publication date
MXPA06014970A (es) 2007-03-07
WO2006004696A2 (en) 2006-01-12
JP2008505087A (ja) 2008-02-21
KR20070029276A (ko) 2007-03-13
IL180361A0 (en) 2007-06-03
CN101001638A (zh) 2007-07-18
ZA200700708B (en) 2009-03-25
EP1778266A2 (en) 2007-05-02
EP1778266A4 (en) 2009-09-09
CA2571030A1 (en) 2006-01-12
AU2005260025A1 (en) 2006-01-12
WO2006004696A3 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NO20054534L (no) Leveringssystem for legemiddel og celleterapi
WO2020201041A3 (en) Glucose sensitive insulin derivatives
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
MX2009007723A (es) Medicacion basada en exenatida y dalargina para el tratamiento de diabetes mellitus, su uso y modalidad de tratamiento.
Xu et al. Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats
TNSN08144A1 (en) Kit for parenteral administration of medicaments
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
EA200800338A1 (ru) Профилактика и лечение офтальмологических осложнений диабета
EA201070557A1 (ru) Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
Gadsby New treatments for type 2 diabetes—The DPP4 inhibitors
Kulasekararaj et al. Phase 3 study of danicopan, an oral complement factor D inhibitor, as add-on therapy to a C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with clinically evident extravascular hemolysis
NO20075508L (no) Stannsoporfinpreparater og administrering
NO20075831L (no) Krystallinske faste og amorfe former av (-)- halofenat
Xu et al. Acute efficacy of a novel anti-tissue factor pathway inhibitor antibody BAY 1093884 in hemophilia A mouse severe tail bleeding
Tack et al. Pasireotide in dumping syndrome-results from a phase 2, international, multicentre study
WO2006096079A3 (en) Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus.
Middelbeek et al. Comment on Brethauer et al. Bariatric Surgery Improves the Metabolic Profile of Morbidly Obese Patients With Type 1 Diabetes. Diabetes Care 2014; 37: e51–e52
Hussein Thalidomide, age, and future use in multiple myeloma
Turpie et al. Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: comparison of outcomes of the XAMOS and RECORD studies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application